Shares of Consort Medical plc (LON:CSRT) have been given a consensus recommendation of “Buy” by the seven brokerages that are covering the company, MarketBeat reports. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is GBX 1,178.17 ($15.78).

Separately, Stifel Nicolaus reissued a “buy” rating and set a GBX 1,250 ($16.74) price objective on shares of Consort Medical in a research report on Thursday, November 9th.

Consort Medical (LON CSRT) opened at GBX 1,158 ($15.51) on Monday. Consort Medical has a fifty-two week low of GBX 960 ($12.86) and a fifty-two week high of GBX 1,170 ($15.67).

TRADEMARK VIOLATION WARNING: This story was first posted by American Banking News and is the sole property of of American Banking News. If you are reading this story on another site, it was stolen and reposted in violation of United States and international trademark & copyright law. The original version of this story can be viewed at https://www.americanbankingnews.com/2017/12/04/consort-medical-plc-csrt-receives-consensus-rating-of-buy-from-brokerages.html.

Consort Medical Company Profile

Consort Medical PLC is a contract development and manufacturing organization (CDMO). The Company’s principal activities include designing, development and manufacture of medical drug delivery devices and services for the pharmaceutical industry. The Company operates through two segments: Bespak and Aesica.

Analyst Recommendations for Consort Medical (LON:CSRT)

Receive News & Ratings for Consort Medical plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Consort Medical plc and related companies with MarketBeat.com's FREE daily email newsletter.